StockData

Myriad Genetics vs NeoGenomics

MYGN and NEO side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MYGN and NEO compare

NeoGenomics is the larger company, worth 3.7 times as much as Myriad Genetics ($2.0B against $533M).

NeoGenomics grew revenue faster over the last twelve months (11.1% versus −3.2% for Myriad Genetics).

NeoGenomics keeps more of each dollar of sales as profit, with a net margin of −4.1% compared with −14.0% at Myriad Genetics.

NeoGenomics scores higher on the StockData Score (11 against 6 for Myriad Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMYGNNEO
Size and price
Market cap$533M$2.0B
Share price$5.57$15.41
Change, 1 year−12.3%53.9%
Change, 5 years−79.1%−58.0%
Beta (5Y)−0.100.84
Employees2,7002,500
StockData Score
Total score611 (better)
Valuation score13 (better)
Growth score04 (better)
Performance score33
Health score2 (better)1
Dividend score00
Valuation
P/S0.7× (better)2.5×
P/B1.8× (better)2.5×
FCF yield–−1.4%
Fair value–$19.92
Margin of safety–22.6%
Growth
Revenue growth (TTM)−3.2%11.1% (better)
Revenue growth, 5Y average−0.63%10.4% (better)
Profitability
Gross margin68.8% (better)44.8%
Operating margin−12.2%−6.3% (better)
Net margin−14.0%−4.1% (better)
FCF margin–−3.6%
Return on equity−32.5%−3.9% (better)
Return on invested capital−22.8%−4.6% (better)
Financial health
Debt / equity0.40 (better)0.47
Interest coverage−6.0× (better)−15.2×
Current ratio2.213.53 (better)
Altman Z-score−0.622.32 (better)
Piotroski F-score5 (better)4
Dividends and buybacks
Buyback yield–−0.02%
Shareholder yield0.00% (better)−0.02%
Ownership
Held by institutions94.1%112%
Held by insiders7.2%1.5%
Insider net buying, 12 months$655K (better)−$717K
Short interest, % of float9.5%10.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.